A day after a first day of mobilization marked by a new public takeover offer, the strike continues on Friday, October 18 at Sanofi’s Doliprane production plants, in Lisieux and Compiègne, according to the unions. “The movement continues, there are about fifty of us in front of the place, the determination is still there”Yohann Nicolas, CGT delegate in Lisieux (Calvados), told Agence France-Presse (AFP).
Sanofi announced last week that it was negotiating with the American investment fund Clayton Dubilier & Rice (CD&R) to potentially sell 50% of Opella, its subsidiary that houses around a hundred brands of products sold without prescription around the world, among them Doliprano. On Thursday, the French fund PAI, whose offer had not been accepted last week, increased its bet to buy Opella. a proposal “out of time” who has ” surprised “ The pharmaceutical group.
“The return of the PAI to the negotiations does not change anything”Mr. Nicolás estimated, adding: “It is the plague or cholera that redeems us. A pension fund is still a pension fund, the fears and concerns are still there. » “Colleagues are worried and suffering, they ask questions about their future without getting answers”concluded the unionist.
The production “very impacted”
In Compiegne, “the mobilization continues” In addition, about forty employees were present shortly before ten in the morning and around a hundred were expected at the height of the day, Adil Bensetra, deputy coordinator of Sanofi’s CFDT, told Agence France-Presse (AFP). assures that there is currently no “There is no information that allows us to break camp”.
The unions fear a “social breakdown” for the 1,700 jobs that Opella has on French soil, of which 480 in Compiègne (Oise) and 250 in Lisieux. “We are in a battle of numbers, but what interests employees is the maintenance of social achievements, the sustainability of works and jobs and the possibility of producing in France”AND “No one currently gives these guarantees”he lamented.
“Production is greatly affected”The union member assures that the mobilized personnel are operators and production technicians who are essential for the proper functioning of the work.
According to the mayor of Compiègne, Philippe Marini, “Doliprane manufacturing represents approximately one third of [l’activité] » of this factory.
The president of Sanofi France, Audrey Duval, guaranteed on Thursday the “sustainability” jobs, production centers and Doliprane.
